Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development

Premium

German biotech firm Kinaxo announced this week it has reached an agreement with AstraZeneca to use its mass spectrometry platform to investigate post-translational protein modifications in support of the drugmaker's oncology programs.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

Among Kinaxo's PTM-related products is its PhosphoScout service, which is designed to monitor the response of cellular signal transduction pathways to drug treatments. It also offers custom PTM analysis services and has struck deals with a variety of global pharma companies including Johnson & Johnson, Dalichi-Sankyo, Roche, and Bristol-Myers Squibb.

Kinaxo does its mass spec work on Thermo Fisher Scientific LTQ Orbitrap Velos machines.

Financial terms of the deal were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.